Motixafortide is a synthetic peptide that binds with high affinity to CXCR4, a G protein–coupled receptor, inhibiting the CXCR4–CXCL12 axis and enhancing T-cell infiltration into the tumor microenvironment. Here, CXCR4 is linked to neoplasm.